Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

Nature Medicine

Volumn 12, Issue 10, 2006, Pages 1160-1166

  Leen, Ann M ^a   Myers, G Doug ^a   Sili, Uluhan ^a   Huls, M Helen ^a   Weiss, Heidi ^a   Leung, Kathryn S ^a   Carrum, George ^a   Krance, Robert A ^a   Chang, Chung Che ^b   Molldrem, Jeffrey J ^c   Gee, Adrian P ^a   Brenner, Malcolm K ^a   Heslop, Helen E ^a   Rooney, Cliona M ^a   Bollard, Catherine M ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS; ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; EPSTEIN BARR VIRUS; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MALE; MONOCULTURE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADENOVIRIDAE; ADOLESCENT; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; T-LYMPHOCYTES;

ADENOVIRIDAE; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4;

EID: 33749514632     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1475     Document Type: Article

References (32)

1. Chakrabarti, S. et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99, 4357-4363 (2002).
2. Chakrabarti, S. et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 100, 1619-1627 (2002).
3. Bollard, C.M., Kuehnle, I., Leen, A., Rooney, C.M. & Heslop, H.E. Adoptive immunotherapy for posttransplantation viral infections. Biol. Blood Marrow Transplant. 10, 143-155 (2004).
4. Papadopoulos, E.B. et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330, 1185-1191 (1994).
5. Heslop, H.E., Brenner, M.K. & Rooney, C.M. Donor T cells to treat EBV-associated lymphoma. N. Engl. J. Med. 331, 679-680 (1994).
6. Rooney, C.M. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549-1555 (1998).
7. Walter, E.A. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038-1044 (1995).
8. Einsele, H. et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99, 3916-3922 (2002).
9. Riddell, S.R. et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238-241 (1992).
10. Cobbold, M. et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 202, 379-386 (2005).
11. Peggs, K.S. et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362, 1375-1377 (2003).
12. Gustafsson, A. et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95, 807-814 (2000).
13. Heslop, H.E. et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2, 551-555 (1996).
14. Lion, T. et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 102, 1114-1120 (2003).
15. + T cells. Blood 104, 2432-2440 (2004).
16. + adenovirus-specific T cells: implications for immunotherapy and gene therapy. J. Virol. 77, 6562-6566 (2003).
17. Wang, Q., Strong, J. & Killeen, N. Homeostatic competition among T cells revealed by conditional inactivation of the mouse CD4 gene. J. Exp. Med. 194, 1721-1730 (2001).
18. Khanna, R. & Burrows, S.R. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu. Rev. Microbiol. 54, 19-48 (2000).
19. Wagner, H.J. et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 103, 3979-3981 (2004).
20. Wadell, G., Hammarskjold, M-L., Winberg, G., Varsanyi, T.W. & Sundell, G. The genetic variability of adenoviruses. Ann. NY Acad. Sci. 354, 16-42 (1980).
21. Leen, A.M. et al. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood 103, 1011-1019 (2004).
22. Smith, C.A., Woodruff, L.S., Rooney, C. & Kitchingman, G.R. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum. Gene Ther. 9, 1419-1427 (1998).
23. Gottschalk, S. et al. An Epstein-Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T cell therapy. Blood 97, 835-843 (2001).
24. Busson, P., Edwards, R.H., Tursz, T. ̄ Raab-Traub, N. Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene. J. Gen. Virol. 76, 139-145 (1995).
25. Bollard, C.M. et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus + Hodgkin's Disease. J. Exp. Med. 200, 1623-1633 (2004).
26. Bunde, T. et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J. Exp. Med. 201, 1031-1036 (2005).
27. Wherry, E.J. et al. Homeostatic proliferation but not the generation of virus specific memory CD8 T cells is impaired in the absence of IL-15 or IL-15Ra. Adv. Exp. Med. Biol. 512, 165-175 (2002).
28. Myers, G.D. et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 36, 1001-1008 (2005).
29. Sili, U. et al. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocytes using lymphoblastoid cell lines for adoptive immunotherapy. J. Immunother. 26, 241-256 (2003).
30. Yotnda, P. et al. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 8, 930-937 (2001).
31. Rooney, C.M. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345, 9-13 (1995).
32. Heim, A., Ebnet, C., Harste, G. & Pring-Akerblom, P. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J. Med. Virol. 70, 228-239 (2003).